Kangpu Biological Medicine
Latest round
- Series B
Last raised
- Aug 2023
Total raised
- $53M
Investors
- 9
About Kangpu Biological Medicine
Established in 2011 and based in Shanghai, China, Kangpu Biological Medicine is a medical company that focuses on the development of innovative small molecule targeted immunomodulatory drugs. In 2014, the company screened out the compound KPG-121.S. FDA clinical approval for KPG-121 for the treatment of advanced prostate cancer. Dr. Chuangsheng Ge, the company's co-founder, chairman and CEO, worked in Novartis, Celgene and Schering-Plough. The company engages in the development of innovative small molecule targeted immunomodulatory drugs. The company has established multiple R&D pipelines in the field of diseases such as prostate cancer, myelodysplastic syndrome and diffuse large B-cell lymphoma, etc. The company's small molecule immunomodulatory targeted drugs utilize the mechanism of protein ubiquitination and degradation. The drugs can be used in curing cancer, autoimmune diseases and inflammation.
Who invested in Kangpu Biological Medicine
9 investors across 3 rounds
See all investors in Kangpu Biological Medicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kangpu Biological Medicine
Who invested in Kangpu Biological Medicine?
Kangpu Biological Medicine has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kangpu Biological Medicine raised?
Kangpu Biological Medicine has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Kangpu Biological Medicine last raise money?
Kangpu Biological Medicine's most recent round on record is a Series B, in Aug 2023.
What does Kangpu Biological Medicine do?
Established in 2011 and based in Shanghai, China, Kangpu Biological Medicine is a medical company that focuses on the development of innovative small molecule targeted immunomodulatory drugs.
Where is Kangpu Biological Medicine headquartered?
Kangpu Biological Medicine is headquartered in Hefei, China.
Which VCs invest in companies like Kangpu Biological Medicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Kangpu Biological Medicine's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Kangpu Biological Medicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.